Medical Care

Global Novel T Cell Immunotherapies Market Research Report 2025

The global market for Novel T Cell Immunotherapies was valued at US$ 4820 million in the year 2024 and is projected to reach a revised size of US$ 11350 million by 2031, growing at a CAGR of 13.2% during the forecast period.
Novel T cell immunotherapies refer to innovative approaches that harness the power of T cells, a type of immune cell, to target and eliminate cancer cells or other diseased cells. These therapies are part of the broader field of immunotherapy, which focuses on enhancing the body"s immune system to recognize and fight against specific diseases. Novel T cell immunotherapies often involve the genetic modification or engineering of T cells to enhance their specificity and effectiveness in targeting particular antigens, such as those found on cancer cells.
There is a trend toward expanding the use of T cell immunotherapies beyond hematologic cancers (such as lymphomas and leukemias) to solid tumors. Researchers are exploring ways to enhance the effectiveness of T cell therapies in treating various types of solid tumors.
This report aims to provide a comprehensive presentation of the global market for Novel T Cell Immunotherapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel T Cell Immunotherapies.
The Novel T Cell Immunotherapies market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Novel T Cell Immunotherapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Novel T Cell Immunotherapies companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Atara Biotherapeutics
Allovir
Eureka Therapeutics
Eutilex
Gammadelta Therapeutics
Neximmune
Ose Immunotherapeutics
Tevogen Bio
Windmil Therapeutics
Segment by Type
Activated T-cells
Virus Driven T-cells
Tregs
T-cell Vaccines
Others
Segment by Application
Lung Cancer
Breast Cancer
Cytomegalovirus Infection
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Novel T Cell Immunotherapies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Novel T Cell Immunotherapies Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Activated T-cells
1.2.3 Virus Driven T-cells
1.2.4 Tregs
1.2.5 T-cell Vaccines
1.2.6 Others
1.3 Market by Application
1.3.1 Global Novel T Cell Immunotherapies Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Cytomegalovirus Infection
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Novel T Cell Immunotherapies Market Perspective (2020-2031)
2.2 Global Novel T Cell Immunotherapies Growth Trends by Region
2.2.1 Global Novel T Cell Immunotherapies Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Novel T Cell Immunotherapies Historic Market Size by Region (2020-2025)
2.2.3 Novel T Cell Immunotherapies Forecasted Market Size by Region (2026-2031)
2.3 Novel T Cell Immunotherapies Market Dynamics
2.3.1 Novel T Cell Immunotherapies Industry Trends
2.3.2 Novel T Cell Immunotherapies Market Drivers
2.3.3 Novel T Cell Immunotherapies Market Challenges
2.3.4 Novel T Cell Immunotherapies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Novel T Cell Immunotherapies Players by Revenue
3.1.1 Global Top Novel T Cell Immunotherapies Players by Revenue (2020-2025)
3.1.2 Global Novel T Cell Immunotherapies Revenue Market Share by Players (2020-2025)
3.2 Global Novel T Cell Immunotherapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Novel T Cell Immunotherapies Revenue
3.4 Global Novel T Cell Immunotherapies Market Concentration Ratio
3.4.1 Global Novel T Cell Immunotherapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Novel T Cell Immunotherapies Revenue in 2024
3.5 Global Key Players of Novel T Cell Immunotherapies Head office and Area Served
3.6 Global Key Players of Novel T Cell Immunotherapies, Product and Application
3.7 Global Key Players of Novel T Cell Immunotherapies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Novel T Cell Immunotherapies Breakdown Data by Type
4.1 Global Novel T Cell Immunotherapies Historic Market Size by Type (2020-2025)
4.2 Global Novel T Cell Immunotherapies Forecasted Market Size by Type (2026-2031)
5 Novel T Cell Immunotherapies Breakdown Data by Application
5.1 Global Novel T Cell Immunotherapies Historic Market Size by Application (2020-2025)
5.2 Global Novel T Cell Immunotherapies Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Novel T Cell Immunotherapies Market Size (2020-2031)
6.2 North America Novel T Cell Immunotherapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Novel T Cell Immunotherapies Market Size by Country (2020-2025)
6.4 North America Novel T Cell Immunotherapies Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Novel T Cell Immunotherapies Market Size (2020-2031)
7.2 Europe Novel T Cell Immunotherapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Novel T Cell Immunotherapies Market Size by Country (2020-2025)
7.4 Europe Novel T Cell Immunotherapies Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Novel T Cell Immunotherapies Market Size (2020-2031)
8.2 Asia-Pacific Novel T Cell Immunotherapies Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Novel T Cell Immunotherapies Market Size by Region (2020-2025)
8.4 Asia-Pacific Novel T Cell Immunotherapies Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Novel T Cell Immunotherapies Market Size (2020-2031)
9.2 Latin America Novel T Cell Immunotherapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Novel T Cell Immunotherapies Market Size by Country (2020-2025)
9.4 Latin America Novel T Cell Immunotherapies Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Novel T Cell Immunotherapies Market Size (2020-2031)
10.2 Middle East & Africa Novel T Cell Immunotherapies Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Novel T Cell Immunotherapies Market Size by Country (2020-2025)
10.4 Middle East & Africa Novel T Cell Immunotherapies Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Atara Biotherapeutics
11.1.1 Atara Biotherapeutics Company Details
11.1.2 Atara Biotherapeutics Business Overview
11.1.3 Atara Biotherapeutics Novel T Cell Immunotherapies Introduction
11.1.4 Atara Biotherapeutics Revenue in Novel T Cell Immunotherapies Business (2020-2025)
11.1.5 Atara Biotherapeutics Recent Development
11.2 Allovir
11.2.1 Allovir Company Details
11.2.2 Allovir Business Overview
11.2.3 Allovir Novel T Cell Immunotherapies Introduction
11.2.4 Allovir Revenue in Novel T Cell Immunotherapies Business (2020-2025)
11.2.5 Allovir Recent Development
11.3 Eureka Therapeutics
11.3.1 Eureka Therapeutics Company Details
11.3.2 Eureka Therapeutics Business Overview
11.3.3 Eureka Therapeutics Novel T Cell Immunotherapies Introduction
11.3.4 Eureka Therapeutics Revenue in Novel T Cell Immunotherapies Business (2020-2025)
11.3.5 Eureka Therapeutics Recent Development
11.4 Eutilex
11.4.1 Eutilex Company Details
11.4.2 Eutilex Business Overview
11.4.3 Eutilex Novel T Cell Immunotherapies Introduction
11.4.4 Eutilex Revenue in Novel T Cell Immunotherapies Business (2020-2025)
11.4.5 Eutilex Recent Development
11.5 Gammadelta Therapeutics
11.5.1 Gammadelta Therapeutics Company Details
11.5.2 Gammadelta Therapeutics Business Overview
11.5.3 Gammadelta Therapeutics Novel T Cell Immunotherapies Introduction
11.5.4 Gammadelta Therapeutics Revenue in Novel T Cell Immunotherapies Business (2020-2025)
11.5.5 Gammadelta Therapeutics Recent Development
11.6 Neximmune
11.6.1 Neximmune Company Details
11.6.2 Neximmune Business Overview
11.6.3 Neximmune Novel T Cell Immunotherapies Introduction
11.6.4 Neximmune Revenue in Novel T Cell Immunotherapies Business (2020-2025)
11.6.5 Neximmune Recent Development
11.7 Ose Immunotherapeutics
11.7.1 Ose Immunotherapeutics Company Details
11.7.2 Ose Immunotherapeutics Business Overview
11.7.3 Ose Immunotherapeutics Novel T Cell Immunotherapies Introduction
11.7.4 Ose Immunotherapeutics Revenue in Novel T Cell Immunotherapies Business (2020-2025)
11.7.5 Ose Immunotherapeutics Recent Development
11.8 Tevogen Bio
11.8.1 Tevogen Bio Company Details
11.8.2 Tevogen Bio Business Overview
11.8.3 Tevogen Bio Novel T Cell Immunotherapies Introduction
11.8.4 Tevogen Bio Revenue in Novel T Cell Immunotherapies Business (2020-2025)
11.8.5 Tevogen Bio Recent Development
11.9 Windmil Therapeutics
11.9.1 Windmil Therapeutics Company Details
11.9.2 Windmil Therapeutics Business Overview
11.9.3 Windmil Therapeutics Novel T Cell Immunotherapies Introduction
11.9.4 Windmil Therapeutics Revenue in Novel T Cell Immunotherapies Business (2020-2025)
11.9.5 Windmil Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Novel T Cell Immunotherapies Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Activated T-cells
Table 3. Key Players of Virus Driven T-cells
Table 4. Key Players of Tregs
Table 5. Key Players of T-cell Vaccines
Table 6. Key Players of Others
Table 7. Global Novel T Cell Immunotherapies Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Novel T Cell Immunotherapies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Novel T Cell Immunotherapies Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Novel T Cell Immunotherapies Market Share by Region (2020-2025)
Table 11. Global Novel T Cell Immunotherapies Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Novel T Cell Immunotherapies Market Share by Region (2026-2031)
Table 13. Novel T Cell Immunotherapies Market Trends
Table 14. Novel T Cell Immunotherapies Market Drivers
Table 15. Novel T Cell Immunotherapies Market Challenges
Table 16. Novel T Cell Immunotherapies Market Restraints
Table 17. Global Novel T Cell Immunotherapies Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Novel T Cell Immunotherapies Market Share by Players (2020-2025)
Table 19. Global Top Novel T Cell Immunotherapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel T Cell Immunotherapies as of 2024)
Table 20. Ranking of Global Top Novel T Cell Immunotherapies Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Novel T Cell Immunotherapies Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Novel T Cell Immunotherapies, Headquarters and Area Served
Table 23. Global Key Players of Novel T Cell Immunotherapies, Product and Application
Table 24. Global Key Players of Novel T Cell Immunotherapies, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Novel T Cell Immunotherapies Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Novel T Cell Immunotherapies Revenue Market Share by Type (2020-2025)
Table 28. Global Novel T Cell Immunotherapies Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Novel T Cell Immunotherapies Revenue Market Share by Type (2026-2031)
Table 30. Global Novel T Cell Immunotherapies Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Novel T Cell Immunotherapies Revenue Market Share by Application (2020-2025)
Table 32. Global Novel T Cell Immunotherapies Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Novel T Cell Immunotherapies Revenue Market Share by Application (2026-2031)
Table 34. North America Novel T Cell Immunotherapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Novel T Cell Immunotherapies Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Novel T Cell Immunotherapies Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Novel T Cell Immunotherapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Novel T Cell Immunotherapies Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Novel T Cell Immunotherapies Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Novel T Cell Immunotherapies Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Novel T Cell Immunotherapies Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Novel T Cell Immunotherapies Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Novel T Cell Immunotherapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Novel T Cell Immunotherapies Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Novel T Cell Immunotherapies Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Novel T Cell Immunotherapies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Novel T Cell Immunotherapies Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Novel T Cell Immunotherapies Market Size by Country (2026-2031) & (US$ Million)
Table 49. Atara Biotherapeutics Company Details
Table 50. Atara Biotherapeutics Business Overview
Table 51. Atara Biotherapeutics Novel T Cell Immunotherapies Product
Table 52. Atara Biotherapeutics Revenue in Novel T Cell Immunotherapies Business (2020-2025) & (US$ Million)
Table 53. Atara Biotherapeutics Recent Development
Table 54. Allovir Company Details
Table 55. Allovir Business Overview
Table 56. Allovir Novel T Cell Immunotherapies Product
Table 57. Allovir Revenue in Novel T Cell Immunotherapies Business (2020-2025) & (US$ Million)
Table 58. Allovir Recent Development
Table 59. Eureka Therapeutics Company Details
Table 60. Eureka Therapeutics Business Overview
Table 61. Eureka Therapeutics Novel T Cell Immunotherapies Product
Table 62. Eureka Therapeutics Revenue in Novel T Cell Immunotherapies Business (2020-2025) & (US$ Million)
Table 63. Eureka Therapeutics Recent Development
Table 64. Eutilex Company Details
Table 65. Eutilex Business Overview
Table 66. Eutilex Novel T Cell Immunotherapies Product
Table 67. Eutilex Revenue in Novel T Cell Immunotherapies Business (2020-2025) & (US$ Million)
Table 68. Eutilex Recent Development
Table 69. Gammadelta Therapeutics Company Details
Table 70. Gammadelta Therapeutics Business Overview
Table 71. Gammadelta Therapeutics Novel T Cell Immunotherapies Product
Table 72. Gammadelta Therapeutics Revenue in Novel T Cell Immunotherapies Business (2020-2025) & (US$ Million)
Table 73. Gammadelta Therapeutics Recent Development
Table 74. Neximmune Company Details
Table 75. Neximmune Business Overview
Table 76. Neximmune Novel T Cell Immunotherapies Product
Table 77. Neximmune Revenue in Novel T Cell Immunotherapies Business (2020-2025) & (US$ Million)
Table 78. Neximmune Recent Development
Table 79. Ose Immunotherapeutics Company Details
Table 80. Ose Immunotherapeutics Business Overview
Table 81. Ose Immunotherapeutics Novel T Cell Immunotherapies Product
Table 82. Ose Immunotherapeutics Revenue in Novel T Cell Immunotherapies Business (2020-2025) & (US$ Million)
Table 83. Ose Immunotherapeutics Recent Development
Table 84. Tevogen Bio Company Details
Table 85. Tevogen Bio Business Overview
Table 86. Tevogen Bio Novel T Cell Immunotherapies Product
Table 87. Tevogen Bio Revenue in Novel T Cell Immunotherapies Business (2020-2025) & (US$ Million)
Table 88. Tevogen Bio Recent Development
Table 89. Windmil Therapeutics Company Details
Table 90. Windmil Therapeutics Business Overview
Table 91. Windmil Therapeutics Novel T Cell Immunotherapies Product
Table 92. Windmil Therapeutics Revenue in Novel T Cell Immunotherapies Business (2020-2025) & (US$ Million)
Table 93. Windmil Therapeutics Recent Development
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
Table 97. Authors List of This Report


List of Figures
Figure 1. Novel T Cell Immunotherapies Picture
Figure 2. Global Novel T Cell Immunotherapies Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Novel T Cell Immunotherapies Market Share by Type: 2024 VS 2031
Figure 4. Activated T-cells Features
Figure 5. Virus Driven T-cells Features
Figure 6. Tregs Features
Figure 7. T-cell Vaccines Features
Figure 8. Others Features
Figure 9. Global Novel T Cell Immunotherapies Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Novel T Cell Immunotherapies Market Share by Application: 2024 VS 2031
Figure 11. Lung Cancer Case Studies
Figure 12. Breast Cancer Case Studies
Figure 13. Cytomegalovirus Infection Case Studies
Figure 14. Others Case Studies
Figure 15. Novel T Cell Immunotherapies Report Years Considered
Figure 16. Global Novel T Cell Immunotherapies Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Novel T Cell Immunotherapies Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Novel T Cell Immunotherapies Market Share by Region: 2024 VS 2031
Figure 19. Global Novel T Cell Immunotherapies Market Share by Players in 2024
Figure 20. Global Top Novel T Cell Immunotherapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel T Cell Immunotherapies as of 2024)
Figure 21. The Top 10 and 5 Players Market Share by Novel T Cell Immunotherapies Revenue in 2024
Figure 22. North America Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Novel T Cell Immunotherapies Market Share by Country (2020-2031)
Figure 24. United States Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Novel T Cell Immunotherapies Market Share by Country (2020-2031)
Figure 28. Germany Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Novel T Cell Immunotherapies Market Share by Region (2020-2031)
Figure 36. China Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Novel T Cell Immunotherapies Market Share by Country (2020-2031)
Figure 44. Mexico Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Novel T Cell Immunotherapies Market Share by Country (2020-2031)
Figure 48. Turkey Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE Novel T Cell Immunotherapies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Atara Biotherapeutics Revenue Growth Rate in Novel T Cell Immunotherapies Business (2020-2025)
Figure 52. Allovir Revenue Growth Rate in Novel T Cell Immunotherapies Business (2020-2025)
Figure 53. Eureka Therapeutics Revenue Growth Rate in Novel T Cell Immunotherapies Business (2020-2025)
Figure 54. Eutilex Revenue Growth Rate in Novel T Cell Immunotherapies Business (2020-2025)
Figure 55. Gammadelta Therapeutics Revenue Growth Rate in Novel T Cell Immunotherapies Business (2020-2025)
Figure 56. Neximmune Revenue Growth Rate in Novel T Cell Immunotherapies Business (2020-2025)
Figure 57. Ose Immunotherapeutics Revenue Growth Rate in Novel T Cell Immunotherapies Business (2020-2025)
Figure 58. Tevogen Bio Revenue Growth Rate in Novel T Cell Immunotherapies Business (2020-2025)
Figure 59. Windmil Therapeutics Revenue Growth Rate in Novel T Cell Immunotherapies Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies